- Home
- SIGA vs IMRX Comparison
SIGA vs IMRX Comparison
Compare SIGA & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIGA | IMRX |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.0M | 340.7M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SIGA | IMRX |
|---|---|---|
| Price | $5.17 | $5.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 751.2K | ★ 792.2K |
| Earning Date | 03-10-2026 | 03-06-2026 |
| Dividend Yield | ★ 11.21% | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $224.81 | N/A |
| P/E Ratio | $16.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.81 | $1.10 |
| 52 Week High | $9.62 | $10.08 |
Technical Indicators
Market Signals| Indicator | SIGA | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 54.80 |
| Support Level | $4.81 | $4.83 |
| Resistance Level | $6.98 | $5.36 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 50.00 | 76.74 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.